Is Globus Medical, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Globus Medical, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued given its current metrics, particularly with a P/E ratio of 36, which is significantly higher than the peer average of 18.37 for companies like Masimo Corp. and Lantheus Holdings, Inc. Additionally, the EV to EBITDA ratio stands at 13.54, while peers such as Haemonetics Corp. show a more favorable ratio of 10.38. The PEG ratio of 0.54 suggests that the stock may be overvalued relative to its growth prospects.
In terms of performance, Globus Medical has underperformed compared to the S&P 500 over the year, with a return of -19.40% against the index's 14.08%. This trend continues over longer periods, with a 3-year return of -6.83% compared to the S&P's 81.19%. Overall, the combination of high valuation ratios and poor relative performance suggests that Globus Medical, Inc. is currently overvalued.